---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-007037"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:12:13.758641+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis Q4 clinical test volume up 41% QoQ; Medicare coverage secured for breast cancer

## Summary
- Preliminary Q4 2025 revenue $17-18M; full year revenue $69-70M (2024: $84.6M).
- Clinical test volume of 16,233 in FY2025, up ~400% YoY; Q4 alone 6,183 tests (+41% vs Q3).
- Clinical test revenue doubled to ~$2.0M in FY2025 (2024: $0.8M).
- Cash, equivalents, and short-term investments ~$240M, including $109M from ATM at $8.43/share.
- Secured Medicare coverage for breast cancer surveillance, a key reimbursement milestone.

## SEC filing metadata
- accession: 0001193125-26-007037
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312526007037/0001193125-26-007037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312526007037/psnl-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-007037
- JSON: https://secwatch.observer/filing/0001193125-26-007037.json
- Plain text: https://secwatch.observer/filing/0001193125-26-007037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.